| Expression pattern: |
DN |
| Associated gene: |
TCF21, TET1, TET2, TET family genes, 5hmC |
| Associated microRNA: |
miR-106b-5p |
| Biological function: |
Inhibits HCC cell proliferation, migration, invasion, metastasis and stemness; increases sensitivity to sorafenib treatment. |
| Molecular mechanism: |
Acts as a sponge for miR-106b-5p to relieve repression of TET family genes (TET1/2), increases 5hmC, promotes TCF21 promoter demethylation and upregulates TCF21, thereby antagonizing EMT and suppressing HCC progression; modulates sorafenib sensitivity. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); stemness (inhibits); ceRNA regulation (promotes); m6A modification (not specified) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Clinical Sample Validation; Cohort Study; Survival Analysis; Transfection; CCK8; Colony Formation Assay; Transwell Assay; MTT; In Vivo Animal Model; H&E Staining; Luciferase Reporter Assay; RNA Pull-Down; Western Blot; ISH (In Situ Hybridization); IHC (Immunohistochemistry); IF (Immunofluorescence); Bioinformatics Analysis |
| Clinical significance: |
circMEMO1 level is closely related to OS and DFS; high circMEMO1 predicts better OS and DFS and is an independent prognostic factor; in recurrent HCC patients treated with sorafenib, circMEMO1-low group has worse OS. |
| Description: |
circMEMO1 is down-regulated in HCC and acts as a tumor suppressor by inhibiting proliferation, invasion/metastasis and stemness. It sponges miR-106b-5p to restore TET1/2 and 5hmC, promotes TCF21 promoter demethylation and upregulates TCF21, thereby suppressing EMT and improving sensitivity to sorafenib; higher circMEMO1 predicts better survival. |
| Confidence score: |
0.8824 |